CDR Affinity Maturation (In Silico)

Home ServicesAntibody Design & Engineering (AI)CDR Affinity Maturation (In Silico)

Overview

In silico affinity maturation narrows the mutational space before any library is built. We model the antibody–antigen complex, perform computational saturation mutagenesis across the CDRs and contact positions, score each substitution for its predicted effect on binding and stability, and combine favourable mutations into a ranked variant panel. The practical benefit is focus: tens of designed variants to express and measure instead of a library of millions to screen.

Schematic: modelling covers the variable domains and CDR loops that determine binding, and developability liabilities are mapped across the whole sequence.

Key Advantages

Binding And Stability Scored Together

Mutations are assessed for both affinity and folding stability, because a large fraction of affinity-improving substitutions destabilise the domain.

Orthogonal Scoring Methods

Physics-based energy calculations and language-model or statistical approaches are combined, and mutations favoured by both receive higher confidence than those favoured by one.

Combinations Modelled, Not Assumed

Beneficial single mutations are not simply summed; combinations are modelled to detect the epistasis that frequently makes stacked mutations underperform.

Liabilities Excluded By Design

Substitutions that introduce deamidation, isomerisation, oxidation or glycosylation motifs are filtered out, so the improved variant does not arrive with a new developability problem.

Where This Service Is Used

Improving the affinity of a lead antibody before candidate selection

Designing a focused mutagenesis library informed by computation rather than random diversity

Rescuing affinity lost during humanisation or format conversion

Fine-tuning specificity to reduce cross-reactivity with a close off-target

Identifying the CDR positions that actually carry the binding energy

Methods and Techniques Applied

Antibody–antigen complex modelling, or preparation of an experimental structure where one exists

Interface analysis identifying contact residues and the energetic contribution of each

Computational saturation mutagenesis across CDR and contact positions with energy-based scoring

Machine-learning and language-model scoring for evolutionary plausibility and fitness

Stability assessment of every candidate mutation alongside its predicted binding effect

Combinatorial design with explicit modelling of the combined variants and liability filtering

What We Need From You

Antibody sequences and the antigen sequence or structure

A complex structure if one exists; otherwise complex modelling is included in the scope

Measured affinity for the parent and for any variants already tested, which calibrates the ranking

The improvement target and the number of variants you can express and measure

What You Receive

Position-by-position mutational scan with predicted effects on binding and stability

Ranked single and combination variants with the rationale for each

Structural models showing what each mutation is intended to change at the interface

Liability screening results confirming no new developability risk was introduced

Recommended testing order, designed so that the results discriminate between hypotheses

What We Compute and Report

Position-by-position mutational scan with predicted binding and stability effects

Interface energy decomposition identifying which contacts carry the binding

Combination variant predictions that model epistasis rather than summing single effects

Evolutionary plausibility scores for every substitution considered

Liability screening results confirming no new developability risk was introduced

Interpretation and Limitations

Computational predictions prioritise hypotheses; they do not independently establish binding, biological activity, therapeutic efficacy, safety or clinical validity. Performance depends on input quality, target class, the structural evidence available and the applicability domain of the selected methods. Scores used for ranking are comparative devices and should not be read as measured quantities. All deliverables are for research use only and are not intended for diagnostic or therapeutic use.

Specifications

Item	Specification	Notes
Positions scanned	All CDR and contact residues	Typically 40–70 positions
Variants delivered	20–80 designs	Singles and modelled combinations
Typical turnaround	3–6 weeks	Including complex modelling where required
Expected outcome	Modest fold improvements typical	Large gains occur but cannot be promised

Service Workflow

Step 01

Scientific Consultation

We discuss the objective, the decision it supports and the data you hold. Nothing is quoted before we understand what the result has to answer.

Step 02

Feasibility Review

We check that the data, target class and available structural evidence can support the proposed approach, and say plainly where they cannot.

Step 03

Technical Proposal

Scope, methods, deliverables, timeline and price are confirmed in writing, together with the limitations we expect to report.

Step 04

Computation and QC

The analysis runs on pinned tool versions in a containerised environment, with quality checkpoints and method comparison where that is informative.

Step 05

Report and Follow-Up

You receive the ranked results, the documented methods, the limitations and a proposed validation plan, plus support in interpreting them.

Is This the Right Service for You?

Choose this service when

A lead antibody needs measurably better affinity before candidate selection

Affinity lost during humanisation or format conversion has to be recovered

A focused mutagenesis library should be designed rather than randomised

Consider another service when

Developability rather than affinity is the limiting problem

Full-Length IgG Antibody Design

A library will be built and selected experimentally

Antibody Library Design

What Goes Wrong, and How We Handle It

The failure modes that produce confident-looking results which do not survive the next experiment. Each one is designed against rather than discovered afterwards.

Every substitution is scored for folding stability alongside binding, and the trade-off is reported per mutation.

Case Studies

The situation

The humanised construct had lost roughly twenty-fold affinity relative to the murine parent.

What the work involved

The complex was modelled for both parent and humanised forms, the interface was decomposed per residue, and framework and CDR positions were scanned for substitutions that restored the lost contacts.

What came back

Two Vernier-zone positions accounted for most of the loss. A graded panel of sixteen variants was delivered, spanning full recovery with lower humanness through to partial recovery with germline frameworks retained.

Illustrative of the shape this work takes. Details are generalised, no client or target is identified, and scope and outcome vary with the system in question.

Questions We Are Asked Before Scoping

Note: ICDMO delivers computational (in silico) services. Results prioritise hypotheses for testing; they do not by themselves establish binding, biological activity, efficacy or safety. All deliverables are for research use only and are not intended for diagnostic or therapeutic use. Downstream experimental work is scoped separately and executed through qualified partners.

Get in Touch
about CDR Affinity Maturation (In Silico)

Tell us about the target, the data you hold and the decision the result needs to support. A scientist reviews every enquiry and replies within one business day.

Feasibility reviewed before any scope or price is fixed

Methods, parameters, confidence and limitations in every report

Confidentiality agreement available before data is shared